Reference
- Ueng KC, Lin MC, Chan KC, Lin CS.
Nifedipine gastrointestinal therapeutic system: an overview of its
antiatherosclerotic effects. Expert Opin Drug Metab Toxicol. 2007
Oct;3(5):769-80. DOI: 10.1517/17425255.3.5.769.
- Noda T, Yaginuma T, O’Rourke MF,
Hosoda S. Effects of nifedipine on systemic and pulmonary vascular
impedance in subjects undergoing cardiac catheterization. Hypertens
Res. 2006 Jul;29(7):505-13. doi: 10.1291/hypres.29.505. PMID:
17044663.
- Di Filippo C, Lampa E, Forgione
A,et al. Effects of nifedipine controlled release on blood pressure
and heart rate of spontaneously hypertensive rats. Comparison with
nifedipine standard and with amlodipine [J].Ital Heart J
Suppl,2005,6(5):285-290.
- Jiang S. T., Yu S. Y. Efficacy of
nifedipine extended-release tablets in the treatment of hypertension
combined with diabetes mellitus [J]. Shandong Medicine,
2010,50(21):67-68.
- Murdoch D, Brogden RN. Sustained
release nifedipine formulations; an appraisal of their current uses
and prospective roles in the treatment of hypertension, ischaemic
heart disease and peripheral vascular disorders. Drugs 1991; 41 (5):
737-79
- Ruzicka M, Leenen FH. Relevance of
24 h blood pressure profile and sympathetic activity for outcome on
short- versus long-acting 1,4-dihydropyridines. Am J Hypertens 1996;
9: 86–94.
- Julius S. Sympathetic hyperactivity
and coronary risk in hypertension. Hypertension 1993; 6: 886–93.
- Cohn JN. Sympathetic nervous system
activity and the heart. Am J Hypertens 1989; 2: 353S–356S.
- Tang Shude, Gong Lansheng.
Pharmacodynamics and pharmacokinetics of nifedipine controlled-release
tablets[J]. Shanghai Medicine, 1997(01):23-24.
- PHYSICIAN’S DESK REFERENCE:Product
Information,Pfizer,Inc.Procardia® capsules and Procardia XL®.Thomson
Healthcare, Montvale,NJ 2002).
- Feng L, Hou Hsiao Y, Meng L, et al.
Application of drug utilization analysis of cardiovascular system in
157 hospitals in Yangtze River basin in 2005[J]. Chinese Journal
of New Drugs and Clinics, 2007, 26(3):175
- Chen Biao, Wu Shu Yue, Wang Yan
Ning, et al. Case analysis of severe adverse reactions caused by
short-acting nifedipine[J]. Chinese
Pharmacist,2009,12(8):1136-1137.
- Tang Shude, Gong Lansheng.
Pharmacodynamics and pharmacokinetics of nifedipine controlled-release
tablets[J]. Shanghai Medicine, 1997(01):23-24.
- Li JF, Yan L, Wang XF, Li XT, Zhang
SJ, Zhang LR. Effects of high-fat diet and ABCB1 gene polymorphisms on
the pharmacokinetics of nifedipine in healthy subjects. Chinese
Journal of Pharmacology,2014,30(04):566-569.
- Schuger, B., Brendel, E., Werneman,
et al. Dose-related food interactions observed in a marketed
once-daily nifedipine formulation after a high-fat American breakfast.
Euro J Clin Pharmacol 58, 119-125 (2002)
Table 1. Pharmacokinetic Parameters of nifedipine Test (T) and
Reference (R) Formulations.